By Michael Dabaie

 

Biofrontera AG said the U.S. Food and Drug Administration approved the BF-RhodoLED XL red-light source for photodynamic therapy, sending American depositary receipts of the German company higher.

FDA granted the approval as a combination approval with the company's prescription drug Ameluz. The new, larger BF-RhodoLED XL was approved in combination with Ameluz for the treatment of mild and moderate actinic keratoses--rough scaly patches--on the face and scalp. The new PDT lamp enables the illumination of larger areas, enabling the simultaneous treatment of several actinic keratoses distant from each other.

ADRs were up 9%, to $5.99, in morning trading.

Ahead of the approval by the FDA, the new lamp was protected by several patent applications.

 

Write to Michael Dabaie at michael.dabaie@wsj.com

 

(END) Dow Jones Newswires

October 22, 2021 10:41 ET (14:41 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Biofrontera (XE:B8F)
Historical Stock Chart
From Nov 2021 to Dec 2021 Click Here for more Biofrontera Charts.
Biofrontera (XE:B8F)
Historical Stock Chart
From Dec 2020 to Dec 2021 Click Here for more Biofrontera Charts.